Stargardt Disease Gene Therapy
Emerging therapies for ABCA4-associated juvenile macular dystrophy
This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.
This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göz Hastalıkları department. Book Appointment →
What is Stargardt Disease Gene Therapy?
Stargardt disease (STGD1) is the most common inherited juvenile macular dystrophy, caused by biallelic mutations in the ABCA4 gene encoding a photoreceptor outer segment ATP-binding cassette transporter. ABCA4 dysfunction results in accumulation of bisretinoid byproducts (A2E, all-trans-retinal dimers) in retinal pigment epithelium lipofuscin, causing progressive RPE atrophy and overlying photoreceptor death starting in central macula. Onset typically in childhood or adolescence with progressive central vision loss.
Currently no approved disease-modifying therapy exists. Emerging therapeutic approaches under investigation include: (1) Gene replacement therapy with lentiviral vector (Stargen, EIAV-ABCA4) due to ABCA4 large size exceeding AAV capacity. (2) Antisense oligonucleotide therapy targeting splicing defects (QR-1011 by ProQR for specific c.5461-10T>C mutation, and others). (3) Pharmacologic strategies including ALK-001 (deuterated vitamin A) by Alkeus, designed to slow vitamin A dimerization in retina. (4) Visual cycle modulators (emixustat) attempting to reduce toxic byproduct accumulation. (5) Complement inhibitors for atrophy progression.
Cell-based approaches include human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) transplantation under macular subretinal space, with early-phase trials demonstrating safety. iPSC-derived RPE patches are also under development. While definitive therapy is not yet available, comprehensive supportive care includes vitamin A avoidance, sun protection, low vision rehabilitation, and integration with clinical trial participation.
Symptoms
Risk Factors
When to See a Doctor?
If you experience any of the following symptoms, seek medical attention promptly:
- Progressive vision loss in child or adolescent
- Family history of Stargardt or macular dystrophy
- Reduced visual acuity not corrected by glasses
- Central scotoma
- Difficulty with reading or facial recognition
- Bilateral macular fundus changes
- Yellow-white flecks at posterior pole
- Bull's-eye maculopathy
- Failure of standard ophthalmic correction
- Considering family planning with family history
- Pregnancy planning
- Interest in clinical trial participation
- Concurrent low vision or rehabilitation needs
- Career or educational planning with vision loss
Treatment Methods
Which Department to Visit?
You can visit our Göz Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.
Learn About Göz Hastalıkları DepartmentLet us help you
You can make an appointment with our specialists or contact us for your concerns.
Related Health Topics
Other articles from the same department you may want to explore.
Anaemia
Dahiliye (İç Hastalıkları)
Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.
Iron Deficiency Anaemia
Dahiliye (İç Hastalıkları)
Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.
Vitamin B12 Deficiency
Dahiliye (İç Hastalıkları)
Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.
Hypertension (High Blood Pressure) Management
Dahiliye (İç Hastalıkları)
Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.
Chronic Kidney Disease
Dahiliye (İç Hastalıkları)
Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.
Hepatitis B (HBV)
Dahiliye (İç Hastalıkları)
Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.
Hepatitis C (HCV)
Dahiliye (İç Hastalıkları)
Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.
Fatty Liver Disease
Dahiliye (İç Hastalıkları)
Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.
Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.